Ryan Deschner
Stock Analyst at Raymond James
(4.81)
# 73
Out of 5,072 analysts
19
Total ratings
83.33%
Success rate
43.19%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ryan Deschner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Upgrades: Strong Buy | $92 → $143 | $94.87 | +50.73% | 2 | Nov 19, 2025 | |
| TVRD Tvardi Therapeutics | Downgrades: Market Perform | n/a | $3.89 | - | 2 | Oct 14, 2025 | |
| LQDA Liquidia | Maintains: Strong Buy | $33 → $41 | $32.26 | +27.09% | 4 | Aug 13, 2025 | |
| TRVI Trevi Therapeutics | Maintains: Strong Buy | $29 → $27 | $11.36 | +137.68% | 3 | Aug 8, 2025 | |
| ARDX Ardelyx | Maintains: Outperform | $11 → $12 | $5.72 | +109.79% | 2 | Aug 5, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $52 → $50 | $21.00 | +138.10% | 2 | Aug 1, 2025 | |
| VKTX Viking Therapeutics | Maintains: Strong Buy | $125 → $122 | $35.46 | +244.05% | 1 | Jul 24, 2025 | |
| SPRY ARS Pharmaceuticals | Maintains: Strong Buy | $26 → $28 | $9.28 | +201.72% | 3 | Jan 14, 2025 |
Palvella Therapeutics
Nov 19, 2025
Upgrades: Strong Buy
Price Target: $92 → $143
Current: $94.87
Upside: +50.73%
Tvardi Therapeutics
Oct 14, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $3.89
Upside: -
Liquidia
Aug 13, 2025
Maintains: Strong Buy
Price Target: $33 → $41
Current: $32.26
Upside: +27.09%
Trevi Therapeutics
Aug 8, 2025
Maintains: Strong Buy
Price Target: $29 → $27
Current: $11.36
Upside: +137.68%
Ardelyx
Aug 5, 2025
Maintains: Outperform
Price Target: $11 → $12
Current: $5.72
Upside: +109.79%
Apellis Pharmaceuticals
Aug 1, 2025
Maintains: Outperform
Price Target: $52 → $50
Current: $21.00
Upside: +138.10%
Viking Therapeutics
Jul 24, 2025
Maintains: Strong Buy
Price Target: $125 → $122
Current: $35.46
Upside: +244.05%
ARS Pharmaceuticals
Jan 14, 2025
Maintains: Strong Buy
Price Target: $26 → $28
Current: $9.28
Upside: +201.72%